Download PDF
Drug Res (Stuttg) 2017; 67(03): 179-182
DOI: 10.1055/s-0042-121419
Original Article
© Georg Thieme Verlag KG Stuttgart · New York

Sumatriptan, an Antimigraine Drug, Inhibits Pentylenetetrazol-induced Seizures in NMRI Mice

Abolfazl Jand
1   General Practitioner, Faculty of Medicine, Department of Physiology, Arak University of Medical Sciences, Arak, IR, Iran
,
Mohammad Reza Palizvan
2   Associate Professor, Faculty of Medicine, Department of physiology, Arak University of Medical Sciences, Arak, IR, Iran
› Author Affiliations
Further Information

Publication History

received 13 June 2016

accepted 10 November 2016

Publication Date:
11 January 2017 (online)

Also available at
    Permissions and Reprints

Abstract

Sumatriptan has been used for the acute treatment of migraine attacks. There are many similarities between migraine and epilepsy and the medications used to treat one of these disorders can effectively be used to treat the other. The purpose of this study was to evaluate and compare the anticonvulsant effects of sumatriptan with sodium valproate in NMRI mice. 62 male NMRI mice were divided into 8 groups. The groups consisted of a saline (control) group, 4 intraperitoneally (ip) administered sumatriptan groups (1, 10, 50, and 100 mg/kg, ip), and 3 sodium valproate groups (50, 150, and 300 mg/kg, ip). 20-min after the injection of either saline or one of the drug doses, pentylenetetrazol (100 mg/kg, ip) was injected and seizure parameters were evaluated. The results showed that 300 mg/kg sodium valproate markedly inhibited the seizure stage, whereas none of the sumatriptan doses had any significant effect on this parameter. The latency to stages 2 and 4 of the seizures and the interval between the pentylenetetrazol injection to death was significantly increased by both sodium valproate and sumatriptan.

Sumatriptan is commonly used for the treatment of migraine and also has a protective effect against seizures induced by pentylenetetrazol in mice.

Key words

antiepileptic drugs - GABA - neuropharmacology
 

  • References

  • 1 Bernard S, Chang M, Daniel H et al. Mechanisms of disease epilepsy. New Engl J Med 2003; 349: 1257-1266
    CrossrefPubMedGoogle Scholar
  • 2 Roceanu A, Bajenaru O. Current therapies in episodic migraine management. Romanian Journal of Neurology 2014; 13: 173
    PubMedGoogle Scholar
  • 3 Pace B. JAMA 100 years ago: migraine and epilepsy. JAMA 1998; 279: 1126
    CrossrefPubMedGoogle Scholar
  • 4 Andermann F. Clinical features of migraine epilepsy syndromes. In: Andermann F, Lugaresi E. (Ed.). Migraine and epilepsy. Boston: Butterworths; 1987: 3-29
    Google Scholar
  • 5 Fan C, Lehmann-Horn F, Jurkat-Rott K. Novel Mutation of SCN1A in a German Family Presenting with both Hemiplegic Migraine and Epilepsy. Biophysical Journal 2015; 108: 588a
    PubMedGoogle Scholar
  • 6 Tsuji S. Migraine and epilepsy. Rinshō shinkeigaku 2014; 54: 1003-1005
    PubMedGoogle Scholar
  • 7 Parisi P. The Complex Relationship Between Epilepsy and Headache and the Concept of Ictal Epileptic Headache. Epilepsy Towards the Next Decade: Springer 2015; 139-162
    PubMedGoogle Scholar
  • 8 Hofstra W, Hageman G, de Weerd A. Headache in epilepsy patients: The (un) awareness of this phenomenon among Dutch neurologists. Seizure 2015; 25: 37-39
    CrossrefPubMedGoogle Scholar
  • 9 Bigal M, Lipton R, Cohen J et al. Epilepsy and migraine. Epilepsy & Behavior 2003; 4: 13-24
    PubMedGoogle Scholar
  • 10 Visser WH, de Vriend RH, Jaspers NM, Ferrari MD. Sumatriptan in clinical practice A 2-year review of 453 migraine patients. Neurology 1996; 47: 46-51
    CrossrefPubMedGoogle Scholar
  • 11 Gentile G, Borro M, Simmaco M et al. Gene polymorphisms involved in triptans pharmacokinetics and pharmacodynamics in migraine therapy. Expert Opin Drug Metab Toxicol 2011; 7: 39-47
    CrossrefPubMedGoogle Scholar
  • 12 Goadsby PJ. The pharmacology of headache. Prog Neurobiol 2000; 62: 509-525
    CrossrefPubMedGoogle Scholar
  • 13 Tepper SJ, Rapoport AM, Sheftell FD. Mechanisms of action of the 5-HT1B/1D receptor agonists. Arch Neurol 2002; 59: 1084-1088
    CrossrefPubMedGoogle Scholar
  • 14 Isaac M. Serotonergic 5-HT2C receptors as a potential therapeutic target for the design antiepileptic drugs. Curr Top Med Chem 2005; 5: 59-67
    CrossrefPubMedGoogle Scholar
  • 15 Prendiville S, Gale K. Anticonvulsant effect of fluoxetine on focally evoked limbic motor seizures in rats. Epilepsia 1993; 34: 381-384
    CrossrefPubMedGoogle Scholar
  • 16 Przegaliński E, Baran L, Siwanowicz J. Role of 5-Hydroxytryptamine Receptor Subtypes in the 1-[3-(Trifluoromethyl) Phenyl] Piperazine-Induced Increase in Threshold for Maximal Electroconvulsions in Mice. Epilepsia 1994; 35: 889-894
    CrossrefPubMedGoogle Scholar
  • 17 Statnick M, Maring-Smith M, Clough R et al. Effect of 5, 7-dihydroxytryptamine on audiogenic seizures in genetically epilepsy-prone rats. Life sciences 1996; 59: 1763-1771
    CrossrefPubMedGoogle Scholar
  • 18 Upton N, Stean T, Middlemiss D et al. Studies on the role of 5-HT 2C and 5-HT 2B receptors in regulating generalised seizure threshold in rodents. Eur J Pharmacol 1998; 359: 33-40
    CrossrefPubMedGoogle Scholar
  • 19 López-Meraz M-L, González-Trujano M-E, Neri-Bazán L et al. 5-HT 1A receptor agonists modify epileptic seizures in three experimental models in rats. Neuropharmacology 2005; 49: 367-375
    CrossrefPubMedGoogle Scholar
  • 20 Peričić D, Lazić J, Jembrek MJ et al. Stimulation of 5-HT 1A receptors increases the seizure threshold for picrotoxin in mice. Eur J Pharmacol 2005; 527: 105-110
    CrossrefPubMedGoogle Scholar
  • 21 Browning RA, Hoffmann WE, Simonton RL. Changes in seizure susceptibility after intracerebral treatment with 5, 7-dihydroxytryptamine: role of serotonergic neurons. Ann N Y Acad Sci 1978; 305: 437-456
    CrossrefPubMedGoogle Scholar
  • 22 De La Torre J, Kawanaga H, Mullan S. Seizure susceptibility after manipulation of brain serotonin. Arch Int Pharmacodyn Ther 1970; 188: 298-304
    PubMedGoogle Scholar
  • 23 Löscher W, Czuczwar SJ. Evaluation of the 5-hydroxytryptamine receptor agonist 8-hydroxy-2-(di-n-propylamino) tetralin in different rodent models of epilepsy. Neurosci Lett 1985; 60: 201-206
    CrossrefPubMedGoogle Scholar
  • 24 Pasini A, Tortorella A, Gale K. The anticonvulsant action of fluoxetine in substantia nigra is dependent upon endogenous serotonin. Brain Res 1996; 724: 84-88
    CrossrefPubMedGoogle Scholar
  • 25 Yan QS, Yan SE. Serotonin-1B receptor-mediated inhibition of [3H] GABA release from rat ventral tegmental area slices. J Neurochem 2001; 79: 914-922
    PubMedGoogle Scholar
  • 26 Stean TO, Atkins AR, Heidbreder CA et al. Postsynaptic 5-HT1B receptors modulate electroshock-induced generalised seizures in rats. Br J Pharmacol 2005; 144: 628-635
    CrossrefPubMedGoogle Scholar
  • 27 Wesołowska A, Nikiforuk A, Chojnacka-Wójcik E. Anticonvulsant effect of the selective 5-HT 1B receptor agonist CP 94253 in mice. Eur J Pharmacol 2006; 541: 57-63
    CrossrefPubMedGoogle Scholar
  • 28 Adeoluwa OA, Aderibigbe AO, Agu GO. Pharmacological Evaluation of Central Nervous System Effects of Ethanol Leaf Extract of Olax Subscorpioidea in Experimental Animals. Drug research 2016; 66: 203-210
    Article in Thieme ConnectPubMedGoogle Scholar
  • 29 Cao X, Deng XQ, Shu B et al. Synthesis and Anticonvulsant Activity Evaluation of 4-(2-alkoxy-phenyl)-2, 4-dihydro-3H-1, 2, 4-triazol-3-ones in Various Experimental Seizure Models in Mice. Drug research 2013; 63: 319-325
    Article in Thieme ConnectPubMedGoogle Scholar
  • 30 Łuszczki JJ, Czernecki R, Dudra-Jastrzębska M et al. Influence of agmatine on the protective action of numerous antiepileptic drugs against pentetrazole-induced seizures in mice A. Pharmacol Rep 2009; 61: 252-260
    CrossrefPubMedGoogle Scholar
  • 31 Ferraro TN, Golden GT, Smith GG et al. Mapping loci for pentylenetetrazol-induced seizure susceptibility in mice. J Neurosci 1999; 19: 6733-6739
    CrossrefPubMedGoogle Scholar
  • 32 Kaube H, Hoskin KL, Goadsby PJ. Inhibition by sumatriptan of central trigeminal neurones only after blood-brain barrier disruption. Br J Pharmacol 1993; 109: 788-792
    CrossrefPubMedGoogle Scholar
  • 33 Humphrey P, Feniuk W, Marriott A et al. Preclinical studies on the anti-migraine drug, sumatriptan. Eur Neurol 1991; 31: 282-290
    CrossrefPubMedGoogle Scholar
  • 34 Van der Post J, Schram M, Schoemaker R et al. CNS effects of sumatriptan and rizatriptan in healthy female volunteers. Cephalalgia 2002; 22: 271-281
    CrossrefPubMedGoogle Scholar
  • 35 Tfelt-Hansen PC. Does sumatriptan cross the blood–brain barrier in animals and man?. J Headache Pain 2010; 11: 5-12
    CrossrefPubMedGoogle Scholar
  • 36 Chavan VR, Mudium R, Sayana SB. Abolition of seizure provoking effect of sumatriptan by fluoxetine in pentylenetetrazol induced seizures in rats. Asian Journal of Pharmaceutical and Clinical Research 2014; 7: 107-109
    PubMedGoogle Scholar
  • 37 Jacob J, Goadsby P, Duncan J. Use of sumatriptan in post-ictal migraine headache. Neurology 1996; 47: 1104
    PubMedGoogle Scholar
  • 38 Bagdy G, Kecskemeti V, Riba P et al. Serotonin and epilepsy. J Neurochem 2007; 100: 857-873
    CrossrefPubMedGoogle Scholar
  • 39 Jobe PC, Dailey JW. Genetically Epilepsy-Prone Rats (GEPRs) in Drug Research. CNS Drug Rev 2000; 6: 241-260
    PubMedGoogle Scholar
  • 40 Dailey J, Mishra P, Ko K et al. Serotonergic abnormalities in the central nervous system of seizure-naive genetically epilepsy-prone rats. Life sci 1992; 50: 319-326
    CrossrefPubMedGoogle Scholar
  • 41 Baillie LD, Ahn AH, Mulligan SJ. Sumatriptan inhibition of N-type calcium channel mediated signaling in dural CGRP terminal fibres. Neuropharmacology 2012; 63: 362-367
    CrossrefPubMedGoogle Scholar
  • 42 Gasior M, White NA, Rogawski MA. Prolonged attenuation of amygdala-kindled seizure measures in rats by convection-enhanced delivery of the N-type calcium channel antagonists ω-conotoxin GVIA and ω-conotoxin MVIIA. J Pharmacol Exp Ther 2007; 323: 458-468
    CrossrefPubMedGoogle Scholar